Bacterial Expression Services
Rapid and cost-effective production of large amounts of proteins usually requires bacterial expression system. The technology development of this system is relatively perfect, which is suitable for the expression of proteins from different species, and has great advantages for the production of proteins with small molecular weight. But there are some problems with the system, such as: The poor compatibility between some expression vectors and strains may result in no or low expression of target proteins; The expressed target protein is insoluble and easy to form inclusion bodies;
Proteins produced from bacterial expression systems usually contain endotoxins, which are difficult to be effectively removed by conventional methods.
In order to ensure the production and quality of each recombinant protein, BioMetas has developed a complete toolbox to tackle any such challenges and to provide best-in-class protein engineering services, providing one-stop service from sequence design, plasmid construction, cell expression, to protein purification, as well as endotoxin removal and other additional services.
Our scientists have rich experience in prokaryotic expression and purification. By selecting different host expression systems (Escherichia coli and Bacillus subtilis), different expression vectors containing multiple fusion labels (His, Trx, GST, Sumo, Flag, MBP, etc.), different cell lines (BL21,Rosetta,C41,WB800, etc.), optimizing the expression conditions, and refolding, etc., greatly solve the problem of prokaryotic expression system.
- Highlights
- Multiple vectors and hosts to ensure soluble protein expression and protein activity
- Purity>95% for most cases
- Endotoxin level can be controlled as low as 1EU/mg
- Turnaround time : 3-5 weeks
Available Strains
Case Study
2-subunit complex
Quinary complex (E.coli)
The traditional approach to target based small molecule drug discovery strongly depends on the in vitro screening of disease relevant proteins as single polypeptide chains. But in vivo , most of the disease targets being pursued by the pharmaceutical industry are not proteins that act in isolation. They are rather acting as part of multi-protein complexes. Determination of the subunit composition, stoichiometry and status of posttranslational modifications ideally are the starting point for cloning, expression and purification of the disease target as a relevant protein complex in the desired functional state. BioMetas provides many choices of expression systems for multiprotein complexes generation.
Above are two example of protein complex produced in e.coli system.